Abstract
ATAGI has provided clinical advice on the use of Nirsevimab (Beyfortus, Sanofi-Aventis) for the prevention of severe disease due to respiratory syncytial virus (RSV) infection in infants.
Recommendation
Western Pacific
Australia
Children
RSV (Respiratory syncytial virus)
